Exposure accumulation drives age-dependent disease architectures and polygenic risk scores

Xilin Jiang[1,2,3,4,5,*], Alkes L. Price[3,4,6], John Danesh[1,2,7,8,9,10], Gil McVean[11], Michael Inouye[1,2,7,9,12,13], Sarah Urbut[4,14], Arun Durvasula[15,16,17,*]

1. British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge UK
2. Victor Phillip Dahdaleh Heart and Lung Research Institute University of Cambridge, Cambridge UK
3. Department of Epidemiology, Harvard T.H. Chan School of Public Health Boston MA USA
4. Broad Institute, Cambridge, MA USA
5. Cambridge Centre for AI in Medicine, University of Cambridge, Cambridge UK
6. Department of Biostatistics, Harvard T.H. Chan School of Public Health Boston MA USA
7. British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
8. National Institute for Health and Care Research Blood and Transplant Research Unit in Donor Health and Behaviour, University of Cambridge, Cambridge, UK
9. Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
10. Department of Human Genetics, Wellcome Sanger Institute, Hinxton, UK
11. Ellison Institute of Technology, Oxford, UK
12. Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
13. Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
14. Cardiology Division, Massachusetts General Hospital, Boston, MA USA.
15. Division of Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA
16. Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA
17. Department of Quantitative and Computational Biology, University of Southern California, Los Angeles, California, USA

* Correspondence: xj262@medschl.cam.ac.uk (XJ); arun.durvasula@med.usc.edu (AD)

Abstract

Our understanding of the dependence of the genetic and environmental architecture of common diseases on age is incomplete. Here, we use longitudinal data to quantify age-dependent genetic and environmental components of complex traits and diseases. When applying our approach to 16 UK Biobank quantitative traits (average N=180K), we found environmental variance can accumulate with age, which leads to decreasing heritability with age, following an exposure accumulation model. We find heritability decreases with age for 5 traits, including systolic blood pressure and lung function (FEV1/FVC), with an average change of -17.8% with age per 10-years. When analyzing complex diseases, we found evidence that environmental variance in disease liability also accumulates with age for 5 of 9 diseases, with an average decrease of heritability -18.1% per 10 years. We found a liability-threshold model with exposure accumulation explains 86% of decreasing PRS prediction R^2 with age in 9 UK Biobank complex diseases. Finally, we show that both genetic and non-genetic predictors have decreasing prediction accuracy with age in 61 predictor-disease pairs, consistent with simulations. Our results suggest ascertaining younger cohorts is more powerful for training both genetic and non-genetic risk prediction models.

Introduction

The extent to which genetics and environmental exposures interact with age when contributing to phenotypic variation in a population is unclear. Previous studies have found evidence that environmental exposures can account for more phenotypic variation in older individuals, potentially due to the accumulation of exposures as people age[1–3]. However, measuring the relevant environmental exposures throughout an individual's lifetime remains a significant challenge. On the other hand, gene-age interaction, which can arise from multiple sources[4], including proportional amplification of genetic variance[5] and different age profiles of genetic effects across genotypes[6], could drive age-dependent phenotypic variation. Jointly studying the age profiles of genetic and non-genetic components of complex traits can elucidate the architectures of age-dependent complex traits.

Recent work has shown age-varying prediction accuracy for polygenic risk scores (PRS), but whether this observation is driven by gene-age interactions or other mechanisms is unknown[6–12]. Significant challenges remain in studying age-dependent disease architectures. First, disease liability is not observed and performing gene-age interaction tests on binary disease observations may not be informative of interactions on the liability scale[13]. Second, although methods exist reduce bias in modeling time-to-event data due to censoring, these methods often have assumptions that are not met in empirical data[6].

Here, we estimated the age-dependent profiles of genetic and environment components of complex traits and disease liability. We show that the impact of environmental exposures accumulates with age for a wide range of complex traits and diseases, which causes a decrease in heritability with age. We show that exposure accumulation, under a liability-threshold model[14,15], explains decreasing prediction accuracy of PRS prediction accuracy for 9 diseases in UK Biobank. Finally, we show by simulation and analytical derivation that a liability-threshold model predicts that both genetic and environmental factors will have decreased prediction accuracy for older cases, which we validate in empirical data using 61 predictor-disease pairs.

Results

Overview of methods

We study age-dependent trait architecture under an exposure accumulation (EA) model where liability is linear in genetic, environment, and age quintiles[16], with environmental variance accumulating with age.

The EA model can be formalized under the following:

$$L = G + E + age + \sum_{a=0}^{age} E_a, \tag{1}$$

where L denotes liability, G is the genetic component of liability, E is the environmental

component, age is the quintile of age, and E_a is the contribution of age to liability. $\sum_{a=0}^{age} E_a$ is

the term arising from the EA model. We study architecture across age quintiles to relax statistical

assumptions on the relationship between age and L. We evaluate evidence for 4 additional

models that can cause an age-dependent architecture: proportional amplification[5,13] (ref), age-

dependent G, exposure accumulation with decay, and non-proportional amplification

(**Supplementary Table 1**).

We evaluate evidence of the EA model by estimating age-varying heritability ($\Delta h^2 = h^2_{older} -$

$h^2_{younger}$), which is negative under the EA model. We estimate Δh^2 by estimating the heritability

for each age quintile with BOLT-REML[17] and fitting a model where heritability changes linearly

with age. We estimate heritability with age and sex as covariates to account for within age

quintile variation due to age and sex. We test for non-zero Δh^2 with a likelihood ratio test

between the model with age term and a null model where heritability is constant with age. We

also evaluate the environmental correlation between age quintiles ($\rho(E_{younger}, E_{older})$), which is

expected to be less than 1.0 under the EA model. We use phenotypic correlations (ρ_l), which is

an upper bound of $\rho(E_{younger}, E_{older})$ under the EA model, to evaluate evidence of

$\rho(E_{younger}, E_{older}) < 1$. We account for error-in-measurement of ρ_l by computing the denoised

phenotypic correlation ($\tilde{\rho}_l$) for individuals with three phenotype measurements at different age

points. We estimated $\tilde{\rho}_l$ as the ratio of first-third visit ρ_l and first-second visit ρ_l. The ratio

cancels the impact of measurement error. We divide $log(\tilde{\rho}_l)$ by the average age difference

between the second and third visits to estimate $\tilde{\rho}_l$ between individuals with one year of age

difference (see **Methods**).

We estimated Δh^2 and $\tilde{\rho}_l$ for 16 quantitative traits across 180K individuals in the UK Biobank

(**Supplementary Table 2**); the sample size reflects a restriction to individuals of British ancestry

with diagnostic records from both primary care data and hospital inpatient data, which we

imposed to mitigate the impact of missing diagnoses. The quantitative traits in this study were

selected following ref. [18] (**Methods**). We use *cross-sectional design* to estimate Δh^2, where we

compare individuals with different ages at the baseline visit. We evaluate the impact of

recruitment bias that can arise from a cross-sectional design in a secondary analysis. We use

longitudinal measurement to estimate $\tilde{\rho}_l$, where we compare multiple measurements at different

age points of the same individual.

We estimate Δh^2 for the estimated disease liability of 9 diseases (**Supplementary Table 3**). We

use 36 quantitative traits (**Supplementary Table 4**) to estimate disease liability at baseline age

by predicting binary disease phenotypes from the quantitative traits. We do not estimate $\widetilde{\rho}_l$ for

estimated disease liability because we do not have longitudinal measurements for all quantitative

traits that were used to estimate disease liability.

We study the impact of age-dependent disease architecture on disease prediction using

simulations. We extract age-at-diagnosis for each patient using the first diagnosis in either

primary care data or hospital inpatient data to evaluate age-dependent disease prediction

accuracy in empirical data. We construct PRS and non-genetic predictors using five-fold cross

validation without age stratification. We have publicly released summary data of age-specific

heritability, phenotypic correlation, and genetic correlation estimates (see **Data Availability**).

We have also released software to compute age-dependent heritability and prediction accuracy

(and **Code Availability**).

Age-dependent genetic architecture of quantitative traits

We estimated Δh^2 w.r.t. age of 16 quantitative traits (**Supplementary Table 2**) to evaluate the

evidence supporting the EA model. First, we found 5 of the 16 traits have significantly

decreasing heritability with age ($p<0.05/9$, FEV1/FVC, LDL cholesterol, total cholesterol,

diastolic blood pressure, and systolic blood pressure) with an average 10-year decrease of 17.8%

in h^2 (**Figure 1A**, **Supplementary Table 5, Supplementary Figure 1**). Second, we computed

genetic and environmental variance of each age quintile using heritability and phenotypic

variance estimates (**Figure 1B, Supplementary Figure 2, Supplementary Figure 3,**

Supplementary Table 6, Supplementary Table 7). We estimated phenotypic variance for

males and females separately to account for sex differences[5,13], which provides estimates for 32

trait-sex pairs. We found $\Delta var(E)$ is significantly larger than $\Delta var(G)$ for 10 trait-sex pairs (red

dots in **Figure 1B**), supporting the EA model. We found $var(E)$ and $var(G)$ vary proportionally

with age in traits that do not have significant age-varying heritability (grey dots in **Figure 1B**),

supporting a proportional amplification model that has been observed in GxE studies[5,13]. The EA

model will move traits above the diagonal line in **Figure 1B**, while the proportional

amplification model will move traits along the diagonal line. Taken together, we conclude that

FEV1/FVC, LDL cholesterol, total cholesterol, systolic blood pressure, and diastolic blood

pressure show evidence for the EA model.

Next, we estimated genetic and phenotypic correlations between age groups to evaluate

additional evidence in support of the EA model. $\rho(G_{younger}, G_{older})$ is expected to equal 1.0 and

$\rho(E_{younger}, E_{older})$ is expected to be less than 1.0 under the EA model. We found the genetic

correlation, $\rho(G_{younger}, G_{older})$, was close to 1.0 for most traits, with exceptions of HbA1c

($p=$1e-4) and glucose ($p=$3e-4) (**Figure 2A, Supplementary Table 8**). A genetic correlation less

than 1.0 supports a model where genetic components have different age profiles

(**Supplementary Table 1**), which is consistent with our previous work that showed that genetic

variants have distinct age profiles in conveying common disease risk[4]. We computed the

denoised phenotypic correlation $\widetilde{\rho}_l$ to evaluate the environmental correlation across age

($\rho(E_{younger}, E_{older})$) (**Methods**). For the 11 traits that have longitudinal data for 3 visits, 7 have

$\widetilde{\rho}_l$ significantly less than 1.0 (**Figure 2B, Supplementary Table 9**), supporting the EA model. $\widetilde{\rho}_l$

has high correlation with Δh^2 w.r.t. age ($\rho=0.61$ across 11 traits, **Figure 2C**), which is consistent

with the EA model. Specifically, the 3 traits (Systolic BP, Diastolic BP, and FEV1/FVC) that

show evidence supporting the EA model in **Figure 1** have the largest difference between $\widetilde{\rho}_l$ and

1. Our analysis of the genetic and environmental correlation between young and old individuals

provides orthogonal evidence in support of EA for systolic blood pressure, diastolic blood

pressure, and FEV1/FVC.

We performed six secondary analyses to test the robustness of our results. First, we tested

whether age-dependent recruitment bias of individuals with different health status could explain

decreasing heritability estimates. We created two age-matched samples (mean age: 55.9 vs. 56.6)

with high and low numbers of prevalent disease diagnoses (mean diagnoses: 6.8 vs 34.6) and

estimated the heritability of 16 quantitative traits in the two groups. We observed minimal

heritability differences between the two groups, which suggests that biased recruitment of

healthier older individuals in the UK Biobank[19] does not contribute to the decreasing heritability

estimates with age (**Supplementary Figure 4**). Second, we evaluated the amplification

models[5,11] by estimating changes in genetic variance w.r.t. age for 32 trait-sex pairs

(**Supplementary Figure 2, Supplementary Table 7**). We found 25 traits with age-varying

genetic variance, align with previous GxSex and GxE studies that report amplifications[5,13].

Third, we tested an alternative model where exposure accumulation decays with age by

identifying traits with Δh^2 close to zero but a denoised phenotypic correlation less than 1.0

across age bins. We found evidence support this model for BMI and body WHR among the traits

that we can estimate $\widetilde{\rho}_l$ (i.e. those with multiple measurements) (**Supplementary Table 9**).

Fourth, we tested a non-proportional amplification model by identifying traits with both genetic

correlation and denoised phenotypic correlation close to 1 but age-varying heritability

(**Supplementary Table 9**). We found no such traits among the traits that we can estimate $\widetilde{\rho}_l$.

Fifth, we estimated genetic correlation between the top and bottom age quantiles (median age

difference = 22.0) without meta-analyzing across age bins and found smaller

$\rho(G_{young}, G_{old})$ compared with the meta-analyzed results with larger standard errors

(**Supplementary Figure 5**). Sixth, we tested whether using age in years instead of age quintiles

can explain more variance in quantitative traits. We found age quintiles explains similar R^2 as

age in years (**Supplementary Figure 6A**), suggesting age quintiles capture the majority of age-

related variation while allowing us to use standard methods to compute heritability and genetic

correlations. We found adding an additional age^2 covariate to the age in years explains more

quantitative trait variance (mean $R^2 = 0.024$ across 16 traits) than the model with only linear age
in years (mean $R^2 = 0.022$ across 16 traits).

Taken together, these results support exposure accumulation as the primary driver of age-
dependent architecture in quantitative traits.

Age-dependent genetic architecture of estimated disease liability

We next investigated whether the liability of 9 diseases (**Supplementary Table 3**) is consistent
with the EA model. We estimated disease liability by applying LASSO[20] to 36 quantitative traits
(**Supplementary Table 4**) measured at baseline and predicting disease status in the entire
population (i.e. across all age bins). We use the value predicted by LASSO as estimated liability
to approximate disease liability (**Methods**).

We hypothesized that estimated liability is highly correlated with the true disease liability at the
baseline age, thus can be used to study the age-dependent architecture of disease liability. We
confirmed that the estimated liability achieves high accuracy across nine diseases, with an
average liability-scale correlation of 0.603 (s.d. = 0.206 across nine diseases, **Supplementary
Table 10**) with case-control status. We applied the same methods as in the quantitative trait
analysis to the estimated liabilities to estimate Δh^2 and $\rho(G_{younger}, G_{older})$. We validated that h^2
of estimated liability is similar to the liability-scale h^2 of the respective diseases (**Supplementary
Figure 7**). We found the heritability of the predicted liability significantly decreases for 5 of the
9 predicted disease liabilities (**Figure 3A**, **Supplementary Table 11**, mean Δh^2 = -18.1%±2.7%
for every 10 years of age), which supports the EA model of disease liability. We observe genetic
correlations across age bins ($\rho(G_{younger}, G_{older})$) are significantly different from 1 for coronary
artery disease (CAD) and T2D (**Figure 3B**, **Supplementary Table 12**), which aligns with
previous observations of heterogeneous age profiles in CAD[6] and subtypes of T2D[21–23]. Taken
together, we determined the estimated liabilities of asthma, hypertension, high lipid, COPD, and
high cholesterol follow the EA model.

Simulations implicate factors contributing to age-dependent disease PRS accuracy

We hypothesized that the following 3 factors could contribute to age-dependent disease PRS
accuracy: (i) age-dependent liability under a liability threshold model[6,14]; (ii) prediction of
incident cases (instead of prevalent cases)[24]; and (iii) exposure accumulation under our new EA
model. We refer to these three hypotheses as factors (i) - (iii)

First, the intuition of factor (i) is that older cases have disease liability closer to healthy
individuals compared to younger cases (see **Methods** and **Supplementary Note**). Under the
liability-threshold model (**equation 1**), L increases as the population ages, which causes older

cases to have liability that is closer to the healthy controls compared to the cases that reached the
threshold at a younger age (**Figure 4A**, ref [16]). Therefore, the difference between cases and
controls becomes smaller for the older population, which causes decreasing prediction accuracy.
In **Supplementary Note**, we show that the difference between the genetic values of cases and
controls strictly decreases with age, which aligns with the intuition that liability of older cases is
closer to healthy controls.
255
Second, the intuition of factor (ii) is that excluding prevalent cases at baseline will create
negative correlation between the predictable component and non-predictable component of
disease liability, which reduces prediction accuracy (see **Supplementary Note)**. We note that
there are two ways to define cases and controls at a specific age point (**Figure 4A**). First,
prevalent case association defines cases as individuals who are diagnosed with the disease
before the age point and controls as individuals who have not had a diagnosis of the disease at
least until the age point; prevalent case association is a common choice in constructing genetic
risk scores[18,25–28]. Second, *incident case prediction* defines cases as individuals who are
diagnosed for the first time within a time window after the age point and controls as individuals
who are not diagnosed at least until the end of the time window; incident case prediction is a
common choice in clinical risk prediction[29,30]. We report results from both case-control
definitions but focus on the latter because incident case prediction has more clinical utility.
268
269   Third, the intuition of factor (iii) is that PRS prediction accuracy decreases with age when
270   heritability decreases with age (see **Supplementary Note**). Under the proposed EA model,
271   heritability will decrease due to exposure accumulation, causing decreasing PRS accuracy with
272   age.
273
We performed simulations to evaluate the contribution of factors (i)-(iii) to age-dependent
prediction accuracy. Our simulation framework modeled liability increasing linearly with age.
The age of onset is determined when the liability of an individual reaches a fixed threshold. We
evaluate prediction accuracy using the observed R^2 with 1:1 case-control ratio (R^2_{obs}), area
under the ROC Curve (AUC), liability-scale R^2 (R^2_{liab}), and log odds ratio ($logOR$). Further
details are provided in the **Methods** section.
280
R^2_{obs}, AUC, and $logOR$ all decrease with age for both prevalent case association and incident
case prediction, while R^2_{liab} decreases with age for incident case prediction but not for prevalent
case association, supporting the contribution of factor (i) to age-dependent prediction accuracy
(orange and purple curves in **Figure 4B; Supplementary Figure 8A**). Incident case prediction
accuracy decreases more than the prevalent case association accuracy, supporting the
contribution of factor (ii). We found that prediction accuracy under the EA model decreases
more than under linear liability-threshold model, supporting the contribution of factor (iii) (grey
curves in **Figure 4B)**. We estimated R^2_{liab} under a normal distribution assumption[31] in empirical

data analyses. We evaluated the accuracy of this approximation using simulations and found it
was accurate (**Supplementary Figure 8B**).
291
We show in the **Supplementary Note** that the *relative* contribution of factor (i) to age-dependent
prediction accuracy depends on the R^2_{liab} of the predictor to the underlying L. To validate this
hypothesis, we simulated predictors with varying R^2_{liab} to the underlying L, representing a
perfect predictor ($R^2_{liab} = 99\%$), a strong predictor ($R^2_{liab} = 50\%$), a clinical score ($R^2_{liab} = $
20%), and a PRS ($R^2_{liab} = 5\%$). Prediction accuracy decreased more steeply with age for
weaker predictors, while the difference is negligible between the clinical risk score and PRS
(**Figure 4C, Supplementary Figure 8A**).
299
300   Our analyses show that prediction accuracy decreases with age under the liability-threshold
301   model (factor (i)) using both analytical results and simulations, while the decreasing slope is
302   steeper when predicting incident cases (factor (ii)), predicting phenotypes that follow the EA
303   model (factor (iii)), and the predictors have low overall R^2_{liab}.
304
305   *Age-dependent prediction accuracy of PRS is partially consistent with liability-threshold model*
306   *and prediction of incident diseases*
307
We next evaluated whether the age-dependent disease PRS accuracy is consistent with factor (i)
and (ii) in empirical data. We computed PRS using BOLT-REML with fivefold cross validation
for 9 diseases without age stratification. We divided the cases into age quintiles based on the
earliest diagnosis age of each patient and created sample sets with a 1:1 case-control ratio to
ensure each age bin has the same sample size and case-control ratio. We computed 4 metrics to
measure incident case prediction accuracy: log hazard ratio ($logHR$), log odds ratio ($logOR$), the
effect size of PRS in a linear regression on case-control status, and R^2_{obs}. We also compute
R^2_{obs} for prevalent case association using the median age of each age quintile as the age index.
We report the change of the 4 metrics ($logHR$, $logOR$, linear regression effects, and R^2_{obs}) by
fitting a model where the metric changes linearly with age. Briefly, we test for non-zero changes
in each metric with a likelihood ratio test between the model with age term and a null model
where the metric is constant with age (**Methods**). We report the 10-year change of each metric
relative to the estimates in the entire population.
321
We found PRS accuracy decreases with age across all diseases we studied, consistent with factor
(i). We started by evaluating the $logHR$ of each PRS to account for censoring. We found that the
$logHR$ of each PRS significantly decreased with age for 6 of the 9 diseases (p<0.05/9, **Figure**
5A, **Supplementary Table 10**), which aligns with a previous study that used lead GWAS
associations and observed decreasing effect sizes with age[6]. On average, the $logHR$ of each PRS
in the oldest quintile was 51%±5% of the youngest quintile. For example, the $logHR$ of the PRS
for predicting hypertension was 0.39±0.01 for the youngest quintile of cases (median(age$_{onset}$) =

47.1) and 0.16±0.01 for the oldest quintile of cases (median(age_{onset}) = 72.2). The $logHR$ of the
PRS for predicting T2D is 0.32±0.02 for the youngest quintile of cases (median(age_{onset}) = 47.7)
and 0.22±0.02 for the oldest quintile of cases (median(age_{onset}) = 72.8). These observations were
consistent across different prediction accuracy metrics of PRS (R^2_{obs}, $logOR$, and linear
regression effects, **Supplementary Figure 9, Supplementary Figure 10,** and **Supplementary**
Table 13). We focus on R^2_{obs} in later sections because it is on the same scale as h^2. We found
the average 10-year decrease for incident case prediction accuracy (R^2_{obs}) was greater than the
10-year decrease in accuracy for prevalent case association (**Figure 5B, Supplementary Table**
14), consistent with simulations of factor (ii) in **Figure 4B** (orange curves versus purple curves,
respectively). For example, R^2_{obs} for PRS predicting hypertension decreases 50.0%±1.7% every
10 years of age in incident case prediction and 26.8%±3.3% for prevalent case association. R^2_{obs}
for PRS predicting T2D decreases 25.1%±4.2% every 10 years of age in incident case prediction
and no longer decreases for prevalent case association (slope= -2.9%±4.2% per 10 years). Our
analyses indicate that PRS prediction accuracy generally decreases significantly with age.
343
344   *Exposure accumulation substantially impacts age-dependent disease PRS accuracy*
345
We next evaluated whether the liability-threshold model (factor (i)), for incident case prediction
(factor (ii)), and the EA model (factor (iii)) can explain age-dependent disease PRS accuracy in
empirical data. We focus on incident case prediction so that all reported age-dependent
prediction accuracy contains the contribution of factor (ii). We create quantitative risk scores
(QRS) using quantitative traits to predict diseases. Because quantitative traits contain both
genetic and non-genetic information, QRS does not contain the impact of the EA model.
Therefore, age-dependent QRS prediction accuracy represents the contribution from factor (i)
and factor (ii). We used the same 36 baseline quantitative traits to create QRS for each disease
and add Gaussian noise so that QRS and PRS have the same R^2_{liab} in the entire population
(**Methods**). We compute the proportion of observed decrease in PRS accuracy with age that can
be explained by each model to evaluate the contribution of the factor (i)-(iii) (**Methods**).
357
We found the liability-threshold model (factor (i)) and EA models (factor (iii)) together explain
the observed age-dependent prediction accuracy of PRS for incident case prediction (factor (ii)).
First, under the liability-threshold model for incident case prediction (factor (i)+(ii)), predictors
using genetic data and predictors using non-genetic data (*i.e.* measurements of quantitative traits
and environmental exposures) are expected to have the same age-dependent prediction accuracy,
if they explain the same amount of variance in the liability (R^2_{liab}) (**Figure 4C**). We used the
change of QRS R^2_{obs} with age to estimate the contribution from factor (i) + (ii) (**Methods**). We
found 65.1%±11.3% of the change of PRS R^2_{obs} with age are explained by these two factors
(**Figure 6A**, **Supplementary Table 15** and **Supplementary Table 16**). The change of QRS
R^2_{obs} with age is significantly different from the change of PRS R^2_{obs} with age for hypertension
(p=6e-8), asthma (p = 9e-13), and CAD (p = 7e-7). We determined that factor (i) + (ii) explains

most, but not all of the decreasing PRS prediction accuracy. Second, under the EA model (factor

(iii)), the heritability of disease liability decreases with age, which causes PRS (which only

captures genetic variance) accuracy to decrease with age. We found Δh^2 of disease liability is not

large enough to fully explain the decrease in PRS prediction accuracy (**Figure 6B**), suggesting

the EA model in disease liability (factor (ii)) is insufficient to explain all of decreasing PRS

prediction accuracy.

Lastly, we combine the effect of EA model with liability-threshold model by computing the

product of QRS R^2_{obs} and h^2 of predicted liability as the expected prediction accuracy of PRS,

which captures the contribution of factors (i), (ii), and (iii). We determined that 85.8%±9.8% of

the observed age profiles of PRS is explained by the factor (i)+(ii)+(iii) (**Figure 6C,**

Supplementary Table 17). A model with factors (i)+(ii)+(iii) explains significantly more

observed $\Delta R^2_{obs}(PRS)$ with age than the model without factor (iii) (p = 4e-6). We note that

CAD cannot be explained by our models (p = 3e-7 for x and y difference in **Figure 6C**). CAD

also has $\rho(G_{younger}, G_{older}) < 1.0$ (**Figure 3B**), suggesting that age-dependent genetic

heterogeneity might cause the deviation from the liability-threshold + EA model. Taken together,

our results suggest that the liability-threshold (factor (i)), incident case prediction (factor(ii)), and

the EA model (factor (iii)) explain age-dependent prediction accuracy of PRS.

Age-dependent accuracy of non-genetic predictors of disease

We investigated whether the liability-threshold model applies to age-dependent accuracy of both

genetic and non-genetic predictors. We constructed risk predictors using the 36 quantitative

measurements as non-genetic variables to further validate the liability-threshold model as a

general model of disease. We note these 36 quantitative measurements contain both genetic and

non-genetic (but predominantly non-genetic), but we use "non-genetic" to distinguish from

analysis that focus on G. For each disease, we constructed 4 predictors with varying prediction

power: (1) "QRS" predictor which is a LASSO predictor that uses all 36 quantitative

measurements, (2) A "Top 3" predictor that is a joint linear predictor trained using the top three

variables ranked by the R^2_{liab} with target disease, (3) "single (strong)" predictors which are the

quantitative measurements that rank 1st-3rd by the R^2_{liab} with target disease, (4) "single

(weak)" predictors which are the quantitative measurements that rank 4th and 5th. We trained all

predictors using five-fold cross validation and estimated their prediction accuracy of diseases in

each age quintile based on baseline UK Biobank visit. We then computed the change of R^2_{obs}

w.r.t. age for each predictor using the same method as the previous sections.

Predictors with greater prediction power in the entire population have less age-dependent

prediction accuracy (**Figure 7A**, **Supplementary Table 18,** and **Supplementary Table 19**), as

predicted by simulation results (**Figure 4C, Supplementary Note**). Relative change of R^2_{obs}

w.r.t. age is -47.6%±1.3% for "single (weak)" predictors (avg(R^2_{liab}) = 9.8%) and -23.6%±1.1%

for "QRS" predictors (avg(R^2_{liab}) = 32.3%), averaging across the 9 diseases. We further expand
to 10 predictors for each disease (QRS, "Top 3", each of the top 5 predictors, "top 2", PRS, PRS
+ QRS, restricting to predictors with R^2_{liab} > 5% for adequate power) and found strong positive
correlations between relative change of R^2_{obs} w.r.t. age and R^2_{liab} across disease-predictor pairs
(**Figure 7B**, slope = 0.64, p =1.2e-5). We conclude that predictors that use environment variables
have decreasing accuracy with age and the effect is stronger for predictors with low overall
prediction accuracy, suggesting combining genetic and non-genetic predictors can increase
prediction power in older populations.
417
418 **Discussion**
419
We systematically quantified age-profiles of genetic and environmental variation to understand
how complex disease architecture and polygenic risk score (PRS) accuracy vary with age. We
found exposure accumulation is common in quantitative traits and complex diseases. We found
the age-dependent PRS accuracy can be explained by a combination of a liability-threshold
model and the exposure accumulation model. Our analysis was enabled by a novel approach to
study estimated disease liability. Finally, we found both genetic and non-genetic predictors
decrease in prediction accuracy with age in empirical data and simulations.
427
Our study represents an advance over previous studies that investigate age-dependent effects.
First, we identify changes in genetic and environmental variance across 16 complex quantitative
traits and 9 diseases. While previous work has studied age-dependent effects, they have focused
on single variant effects[32] or have studied a limited set of phenotypes[12,13,33–39]. Second, to the
best of our knowledge, our work is the first to quantify how environmental variance in complex
traits accumulates with age using longitudinal data. Third, our work is the first to provide a
quantitative explanation for the decrease in prediction accuracy for genetic and non-genetic
predictors. While other studies have observed this phenomenon, they have not been able to
explain it[6,11]. We note, however, that CAD was an exception to the EA model and, while we
speculate that this may be due to age-dependent genetic heterogeneity, this is something of a
mystery to be resolved in subsequent studies. Lastly, our work demonstrates that PRS trained and
tested using prevalent case association[18,25–28] shows different age-dependent accuracy compared
with incident case prediction, underscoring the importance of evaluating PRS accuracy using
incident case prediction, which has greater clinical utility[32–35].
442
Our study has several implications. First, the EA model suggest GWAS study can increase power
by accounting for age-dependent heritability. In particular, we hypothesize that mixed effect
model can increase power by modelling age-specific random effects. Second, the EA model
suggests when incorporating PRS in clinical risk models, PRS should be weighted differently
with age to increase power. Third, our results suggest all predictors (*i.e.* genetic or non-genetic)
of disease have age-dependent accuracy, while predictors with stronger prediction power in the

entire population will have more robust prediction accuracy at older age. This motivates
constructing predictors that combine multiple data modalities to achieve maximal prediction
accuracy across age. Fourth, the observed exposure accumulation suggests genetic effects
contribute more to phenotypic variation at early ages, suggesting ascertaining environment
variables is critical to accurately predict phenotypes at later ages. Lastly, our results suggest
recruiting younger cases can improve power for discovering both genetic and environment
biomarkers for diseases. All of these implications motivate directions for future research.
456
Our study has several limitations. First, our modeling is not able to detect uniformly decreasing
genetic variance which can cause decreasing h^2 with age and $\rho(G_{young}, G_{old})$ close to 1.
However, we believe this is not likely because we found evidence of accumulating
environmental variance in the $\widetilde{\rho}_l$ analyses which explains the decreasing h^2 (**Figure 2C**).
Second, the age range of our study sample is restricted, with baseline visit age between 40 to 79
years of age. Future analyses with a wider age distribution may discover stronger effects. Third,
we use a cross-sectional analysis, which is susceptible to recruitment bias. We tested whether
age-dependent recruitment bias of healthier individuals could explain decreasing heritability
estimates with age and observed minimal heritability differences between the two groups,
suggesting a minimal effect of biased recruitment. Fourth, our analyses uses only individuals of
European individuals. While it is of interest to perform the analysis on individuals of other
ancestries, currently available data of other genetic ancestry might not have sufficient power for
age-stratified analyses. Fifth, our analyses use the UK Biobank data set. It is of interest to
replicate the analysis in other cohorts such as All of Us[36]. Sixth, majority of our findings rely on
the validity of liability-threshold model, although liability-threshold model has been widely
accepted and used[14,15,37–43]. Despite these limitations, our work identifies exposure accumulation
as a key aspect age-dependent disease architecture, and our results explain the decreasing genetic
and non-genetic disease prediction accuracy with age.
475
Methods
Study population in UK Biobank
We used the disease diagnosis information from 180,026 individuals whose primary care data
(General Practice, GP) was available and of British Isle ancestry. The primary care data are
coded in readv2 which were mapped to SNOMED CT
(https://digital.nhs.uk/services/terminology-and-classifications/read-codes), SNOMED CT codes
were then mapped to ICD-10 codes (using NHS digital's code mapping https://digital.nhs.uk/),
which were combined with ICD-10 codes from Hospital Episode Statistics (HES) and mapped to
PheCodes [44]. We extracted the earliest diagnosis age using the earliest records from the
combined primary care and HES data, which are used as age labels in our analysis. The choice of
focusing on individuals with both primary data and HES data was to get the best age at diagnosis
for each disease. When combining GP and HES data to extract diagnosis, correlation between
binary and quantitative traits increased compared to only using HES data to extract disease

(**Supplementary Figure 11**), suggesting that combining GP and HES data capture diagnoses
more accurately as correlation decreases when variables are measured with noise.
491
<u>Selection of quantitative and binary traits</u>
We extracted 36 quantitative traits measured at baseline visit of UK Biobank based on ref. [18]. As
our goal is to study disease liability, we selected 9 diseases using phecodes that have
interpretable underlying quantitative traits from the 36 quantitative traits (e.g. Hb1Ac for T2D,
BMI for obesity, LDLc for hypercholesterolemia) and prevalence higher than 5%
(**Supplementary Table 3**). Disease status and age-at-diagnosis were extracted from GP+HES
data described in the previous section.
499
We corrected blood biochemistry measurement for cholesterol, hypertensive, and diabetic
medications: cholesterol (+1 s.d.), LDL-c (+ 1 s.d.), and triglyceride levels (+0.5 s.d.) were
corrected for lipid lowering medication[45]; systolic blood pressure (+15 mm Hg) and diastolic
blood pressure (+ 10 mm Hg) were corrected for hypertension medication[46]; HbA1c level is
corrected for non-insulin diabetic medication (+ 10.929) and insulin drugs (+ 1.3 x 10.929)[47].
The respective changes for individuals who are taking the medication are in the parentheses after
each trait; s.d. is the standard deviation computed in the entire population. We verified that the
correlation between the corrected quantitative traits and corresponding binary traits is higher
compared to the correlation between uncorrected quantitative traits and the same set of binary
traits. $\rho(LDL, hypercholesterolemia)$: 0.188 post-medication correction vs -0.005 pre-
correction. $\rho(Systolic\ blood\ pressure, hypertension)$: 0.519 post-medication correction vs
0.425 pre-correction. $\rho(HbA1c, T2D)$: 0.565 post-medication correction vs 0.524 pre-correction.
Both corrected and uncorrected values were included in the final 36 quantitative traits.
513
514   In our analyses, smoking status is defined as an ordinal variable with the following values: never
515   (0), previous (1), current (2) (**Supplementary Table 4**).
516
517   To select quantitative traits that are most relevant to the nine diseases, we further computed the
518   correlation between the 36 quantitative traits and the nine disease traits and selected 16 of the 36
519   quantitative traits based on liability-scale correlation [31]; the included quantitative traits are
520   among the top 3 correlated traits for at least one of the nine binary diseases.
521
<u>Heritability and genetic correlation</u>
We estimated heritability using the REML function of BOLT-LMM[17] version 2.4.1. 180,026
individuals were divided into 5 age bins based on the baseline visit age. We performed REML
analysis for each age bin using sex and baseline visit age as covariates; we use the same 536,492
HapMap3 SNPs that have moderate LD with each other which is the same as the PRS section,
see below. We also computed the heritability of 16 quantitative traits and nine diseases in the
entire population.

We estimated genetic correlation between age bins for the 16 quantitative traits using LDscore

regression[48]. First, we used the mixed-effect model to compute summary statistics for each age

bin using BOLT-LMM version 2.4.1. We used the same set of variants and individuals as the

heritability estimation. Since BOLT-LMM is a mixed effect model that controls population

stratification, we constrained the heritability intercept of LDSC to 1.0; we constrained covariance

intercept to be 0 as there is no sample overlap between different age bins. We run cross-trait

LDSC for each age-bin pair (10 pairs in total for 5 age bins) to estimate the genetic correlation

and its standard error.

<u>Testing for heritability changes across age bins</u>

We tested the age-dependency of heritability using heritability estimates with standard error

across the five age bins. We used likelihood ratio tests to identify non-constant heritability across

age bins. We tested two nested models: H_0: $h^2 \sim N(0 \times age + b, s.e.(h^2))$ and

H_1: $h^2 \sim N(a \times age + b, s.e.(h^2))$. We estimated b under H_0 and a, b under H_1 using

maximum likelihood estimators across the five heritability estimates. For each age quintile, we

use the median age to fit the model. The slope a estimated under H_1 are the per year change of

h^2. We use Monte-Carlo sampling of h^2 for each age quintile from a Gaussian distribution with

mean equals to the point estimates and variance equals to s.e.. We estimate a, b of each Monte-

Carlo sample. The s.d. of a estimates across Monte-Carlo samples are the s.e. of the estimates.

We note this approach relies on the fact that samples are non overlapping across age quintiles.

In all analyses, we report the relative change of heritability compared to the heritability estimate

in the entire population.

<u>Testing for genetic correlation less than 1 between age bins</u>

The quantity of interest is the difference between genetic correlation and 1: $1 - \rho_g$. First, we

scale genetic correlation using $\rho_{normalised} = exp(10 \times ln\, \rho_{\Delta age} / \Delta age)$ to account for the

varying age differences of age-bin pairs; the age differences are computed using the median of

each age quintile. Scaling on the exponential scale aligns with a Wiener process of liability w.r.t

age (see below). For 5 age bins, we can estimate 10 genetic correlations between pairs of age

bins; these 10 genetic correlations have four degrees of freedom. Therefore, we use inverse-

variance weighting to meta-analyse four of the 10 scaled ρ_g (we use ρ_g of neighboring age-bin

pairs 1-2, 2-3, 3-4, and 4-5) to compute one 10-year r_g for each trait; standard errors of the 10-

year r_g estimates are used for inverse-variance weights.

<u>Computing phenotypic correlation across age points</u>

Under the assumption that random variance accumulates linearly w.r.t. age (as in a Wiener

process), the correlation between liability across age bins is a function on the multiplicity scale

$\rho_{\Delta age} = e^{-\beta \; \Delta age}$. Therefore, we computed the expected 10-year genetic and phenotypic

correlation by $exp(10 \times ln \, \rho_{\Delta age} / \Delta age)$ to make the correlations comparable for age bin pairs

with different age differences. We computed phenotype correlations across individuals who have

three visits to the UK Biobank. We remove the impact of measurement error by computing a

ratio of two correlations $\rho_{\Delta age} = \rho_l(t_1, t_3) / \rho_l(t_1, t_2)$, which cancels out the measurement

error, and we use the average age difference between second and third visit ($\Delta age = t_3 - t_2$) to

scale the estimate.

<u>Testing the impact of selection in recruitment process</u>

To test for whether the age-dependent heritability changes can be attributed to selected

recruitment of healthier individuals at older age groups[19], we computed the number of past

diagnosis records as an indicator of health status and created samples with matched age but

different past diagnosis. We used health records from both GP and HES, and divided the target

population into two groups, "healthy" versus "unhealthy", using the median number of prevalent

records (median=16). We then use inverse probability weights to sample 45,267 individuals from

both groups, resulting in two samples that have matched age distributions (mean: 55.9 vs. 56.6,

respectively) but different numbers of past diseases (mean: 6.8 vs 34.6, respectively); in

comparison, top and bottom age quintile has an average age of 67.5 and 45.3 and an average of

24.2 and 18.7 of past diseases, respectively. We compute heritability of the 16 quantitative for

both groups using the same procedure as for age quintiles.

<u>PRS construction</u>

We obtained 536,492 HapMap3 SNPs using pruning parameters of window size=50 kb, step

size=5 kb, and r^2 threshold=0.8; selection of SNPs makes mixed effect model computational

tractable. We then used BOLT-LMM to estimate PRS, using genetic sex and age at baseline as

covariates, using 5-fold cross validation for the 9 diseases and 16 quantitative traits. PRS are

scaled to have mean=0 and sd=1 in the entire population.

<u>PRS incident case prediction and prevalent case association</u>

For incident case prediction, we first divided cases into five age quintiles based on their first age-

at-diagnosis; for each age quintile, we define case control status based using interval-censor

procedure [6], where cases are defined as those who are diagnosed within the age interval and

controls are defined as those who remained healthy till the end of age interval or lost to follow up

within the age interval. We then down sampled the controls for each age bin to have the same

number as the cases. As a result, for a given disease, each age interval has exactly the same

number of cases and controls which ensures the odds ratio and hazard ratio are comparable

across each age bin. When evaluating PRS using linear, logistic, and Cox regression models, we

included genetic sex and top five genetic PCs as covariates. When evaluating PRS using

observed-scale R^2, we first regress the outcome on genetic sex and top five genetic PCs, then

compute Pearson's correlation between the residual and PRS; the square of Pearson's correlation
is the observed-scale R^2 with 1:1 case control ratio.

For prevalent cases association, we used the five median case age of the respective age intervals
as the baseline age points and considered all individuals who have been followed up past the
baseline age point. The prevalence cases are defined as those who have at least one diagnosis
record before the baseline age point. We sampled controls to be the same number as cases for
each age point, so that for a given disease, the effect sizes of linear, logistic, and Cox regression
across five baseline age points are comparable. The regression models and observed-scale R^2
were computed using the same covariates as in incident case association.

<u>Estimated disease liability</u>
We use 36 continuous traits measured at baseline to predict the 9 binary disease traits; the
resulting predictor is the *estimated disease liability*. Cases are defined as the union of both
incident and prevalent disease. We use LASSO linear model (instead of logistic regression as we
assume a liability-threshold model) to train the prediction models with 10-fold cross validation;
the regularization coefficients are chosen by the cross-validation with both 1se (default setting of
the R glmnet package[49,50]) and 2se (stronger regularization). We chose the predicted liability
using the 2se model as it has a similar liability-scale correlation (average=0.60 across 9 diseases)
with the binary trait to the 1se model (average=0.61 across 9 diseases), while being more
explainable and less susceptible to overfitting. The models were fitted in the entire population
without including age as a covariate so that the predicted disease liability represents the
approximate disease liability at the age of baseline visit.

We used the same procedure as the quantitative traits analysis to estimate heritability and genetic
correlation for predicted liability. We used BOLT-REML to estimate heritability. We used
BOLT-LMM to compute GWAS summary statistics then use cross-trait LDSC to estimate
genetic correlation of each age-bin pair (10 pairs in total for 5 age bins) to estimate the genetic
correlation and its standard error. We did not constrain intercepts for cross-trait LDSC to avoid
potential bias population relatedness.

<u>Simulation of linear liability-threshold model</u>
We simulated genetic variance G and environment variance E from normal distribution with
mean 0 and variance equal to h^2 and $(1-h^2)$ respectively. Liability L equals the sum of G and E
for each individual. To simulate liability increasing with age, we take 2% of the simulated
individuals with the highest liability as the youngest disease group, top 2-4% of liability as the
second age group and repeated the procedure to obtain five groups of individuals with increasing
onset age. Each disease threshold corresponds to the disease cut off at an age point. Prevalent
cases are defined as the individuals that have liabilities higher than the threshold at a specific age
point; incident cases are defined as individuals in the bin near the liability threshold at a specific

age point (i.e. all individuals with liability near the corresponding liability); controls are defined
as all individuals excluding prevalent cases (i.e. all individuals have liability lower than the
corresponding liability).We simulated 100,000 individuals, with h^2=0.3 and using five age bins
of 2% of individuals, which matches the disease prevalence and sample size in empirical
analyses.

We note our simulation uses percentiles of individuals to represent cases with increasing age,
which aligns with the empirical analysis (see below) where we divided cases into quintiles based
on the diagnosis age. We note under the proportional amplifciation model, the liability percentile
of each individual does not change, which means this model is invariant to proportional
amplification.

<u>Simulation of EA liability-threshold model</u>
We simulated initial liability L using the same procedure as the linear liability-threshold model.
For each age bin, we sample cumulative environmental variance E_a from normal distribution
with 0 mean and 0.05 variance. We then cumulatively add these sampled environmental
variances to the liability when moving to an older age quintile, which will result in 20% more
accumulated variance in the fifth age quintile. In empirical data, we found ~20% decrease in
heritability over 20 years for quantitative traits, which motivates our choice of simulation
parameters.

We defined prevalent cases as individuals who have got disease at any prior age bin or the
current age bin, and incident cases as those who get disease within the current age bin. For each
age bin, we take the top 2% individuals who have not prevalent diseases to simulate that liability
increases with age. We note this simulation procedure makes the number of cases equal to
previous simulation of the linear model so the metrics in **Figure 4B** are comparable.

<u>Estimating age-dependent prediction accuracy under the linear liability-threshold model</u>
We use rank normal transformation of estimated liability to create a *quantitative risk score*
(QRS). QRS combines both G and E information which is different from PRS that only captures
G information; under the linear liability-threshold model, QRS and PRS has the sample age-
dependent prediction accuracy profile when their liability-scale R^2 are equivalent across the
population (**Figure 4C**). We performed the following 6 steps to use QRS to estimate expected
age-dependency of PRS under the liability-threshold model. (1) QRS are rank normal
transformed to have similar distributions as PRS. (2) QRS are adjusted for age at measurement
and genetic sex; PRS are adjusted for first 5 genetic PCs and genetic sex. Adjustment of
covariates ensures QRS and PRS are comparable under the linear liability-threshold model for
each age bin, as QRS will change with age while PRS does not change with age. (3) We
computed the liability-scale R^2 of QRS and PRS using all individuals with primary care
information (N = 215,162); cases are defined as the union of prevalent cases and incident cases.

We computed observed-scale R^2 for both QRS and PRS and transformed observed-scale R^2 to
liability-scale R^2 using equation 14 of ref [31]. (4) We added gaussian noise (mean = 0) to QRS so
that the new QRS has the same liability-scale R^2 as PRS. (5) We computed QRS observed-scale
R^2 for each age bin using the same case-control definition as incident case prediction of PRS. We
note a caveat that some QRS are measured after disease diagnosis. Our choice is based on two
reasons: first, under the linear liability-threshold model, QRS (age and sex adjusted) represents
the liability that remains constant across age; second, observed-scale R^2 for QRS and PRS are
computed using the same samples, making them comparable. We use QRS to predict incident
cases at baseline visit and found similar results, see sections pertains to "non-genetic predictors".
(6) We performed Monte-Carlo sampling to account for two sources of uncertainty: (i) the
process to add noise to QRS and (ii) control sampling within each age bin. We reported mean
and standard deviation of 50 Monte-Carlo sampling estimates for each parameter.

We define the proportion of observed decrease in PRS accuracy explained by each model as:
$$\tau = \sum_{diseases} \max(\Delta R^2_{QRS}, \Delta R^2_{PRS}) / \sum_{diseases} \Delta R^2_{PRS}.$$
The max in the numerator reflects the constraint that the proportion of age-dependent PRS
accuracy that can be explained is less than 100%. Therefore, diseases with more decrease in QRS
accuracy than PRS accuracy are assigned the same value in numerator and denominator. This
choice is justified by empirical data as we do not observe significantly more decrease in QRS
accuracy than PRS accuracy at a nominal p-value of 0.05, except for CAD.

<u>Estimating age-dependent prediction accuracy under the EA + liability-threshold model</u>
We multiplied the estimated slope from QRS with the slope of h^2 of predicted liability to
estimate the expected decrease under the EA + liability-threshold model. Under the EA model
PRS prediction accuracy is proportional to h^2 of disease liability at each age point. The EA +
liability-threshold model estimates capture both the age-dependency from the linear liability-
threshold model (captured by QRS) and the EA model (captured by the Δh^2 of predicted
liability). The expected change is computed as $1 - (1 + \Delta R^2_{QRS}) \times (1 + \Delta h^2_{predicted-liability})$.
We use Monte-Carlo sampling of ΔR^2_{QRS} and $\Delta h^2_{predicted-liability}$ to estimate the standard
error of the estimator; we omit the sampling covariance between ΔR^2_{QRS} and
$\Delta h^2_{predicted-liability}$ as they were estimated from approximately independent information (*i.e.*
ΔR^2_{QRS} were estimated using age quintiles of cases and baseline measurements, while
$\Delta h^2_{predicted-liability}$ uses genetic information).

<u>Incident case prediction with non-genetic predictors</u>
For environment variable predictors, we divided incident cases into five age bins using the age at
first diagnosis visit. We note that in contrast to PRS prediction accuracy, we excluded
individuals who have prevalent cases before baseline visits as environment variables are
measured at baseline visit. The definition of incident cases and controls for each age quintile,
down sampling of control is the same as the PRS incident case prediction. We computed

observed-scale R^2 for each environment predictor by regression of sex and top five genetic PCs from the outcomes and computed Pearson's correlation between the outcome residual and the predictor; the square of Pearson's correlation is the observed-scale R^2 with 1:1 case control ratio.

We analyzed 10 predictors including 9 environment predictors and PRS. We computed the relative change of observed-scale R^2 compared to the observed-scale R^2 estimate in the entire population. Observed-scale R^2 in the entire population were transformed to liability-scale R^2 using equation 14 of ref [31]. When computing the relationship between liability-scale R^2 (in the entire population) to the change of observed-scale R^2, we only include 61 of 90 predictors that have liability-scale R^2 larger than 5% to ensure there is sufficient power to detect age-dependency.

Code Availability

Code to replicate all analyses in the manuscript is available at https://github.com/Xilin-Jiang/GxAge

Data Availability

Summary data in the manuscript is available at https://github.com/Xilin-Jiang/GxAge

Acknowledgements

Use of the UK Biobank data was performed under application number 7439. This research was funded by Wellcome Trust early-career award 227566/Z/23/Z (X.J.) and the National Institute Of General Medical Sciences of the National Institutes of Health under Award Number R35GM16046 (A.D.). M.I. is supported by the Munz Chair of Cardiovascular Prediction and Prevention and the NIHR Cambridge Biomedical Research Centre (NIHR203312) as well as by the UK Economic and Social Research 878 Council (ES/T013192/1). J.D. is supported by a British Heart Foundation Personal Chair. This work was supported by core funding from the British Heart Foundation (RG/F/23/110103), NIHR Cambridge Biomedical Research Centre (NIHR203312), BHF Chair Award (CH/12/2/29428), Cambridge BHF Centre of Research Excellence (RE/24/130011) and by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and the Wellcome Trust. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the National Institutes of Health.

Figure 1. Age-dependent variance of quantitative traits. (A) Heritability changes per 10-years for 16 quantitative traits. Red bars show significant heritability changes across age; error bars show standard error via Monte-Carlo sampling. (B) 10-year change for genetic and environment variance for the 16 quantitative traits. Traits with significant age-dependent heritability are highlighted in red. Traits in grey show evidence of proportional amplification of genetic and environmental variance. Error bars are standard error via Monte-Carlo sampling. Numerical results are provided in **Supplementary Table 5 and Supplementary Table 7**. We note that no estimates are significantly outside the plausible range and that allowing estimates outside of the plausible range is necessary to ensure unbiasedness of estimates.

Figure 2. Genetic liability is more correlated across young and older age groups than
environmental liability. (A) 10-year genetic correlation between younger and older age bins for
16 quantitative traits. We report the genetic correlation per 10-year age difference. (B) Scatter
plot of 10-year genetic correlation versus denoised 10-year phenotypic correlation for the 11
quantitative traits that have three measurements per individual. We found no genetic correlation
or phenotypic correlation that are significantly higher than 1 at nominal p-value = 0.05. (C)
Scatter plot of heritability changes per 10-years versus denoised 10-year phenotypic correlation
for the 11 quantitative traits that have three measurements per individual. Traits with denoised
10-year phenotypic correlation significantly different from 1 are shown in red and labeled in
panel B and C; non-significant traits are shown in grey. Error bars for phenotypic correlation are
standard error via bootstrapping over individuals; error bars for genetic correlation are standard
error after meta-analysis across 4 age-bin pairs. Numerical results are provided in
Supplementary Table 8-9. We note that no estimates are significantly outside the plausible
range and that allowing estimates outside of the plausible range is necessary to ensure
unbiasedness of estimates.

Figure 3. Age-dependent genetic architecture of estimated liability supports the EA model.
(A) 10-year heritability change for estimated liability of 9 diseases; error bars show standard error via Monte-Carlo sampling. (B) 10-year genetic correlation for the estimated liability of 9 diseases. Error bars are standard error via meta-analysis of 10 age bin pairs. Numerical results are provided in **Supplementary Table 11-12**.

Figure 4. Liability-threshold model and the EA model explains age-dependent disease prediction accuracy in simulations. (A) Schematic figure explaining the decreasing disease prediction accuracy with age. In the top panel, each line represents the liability trajectory of an individual. The panel below shows the joint distribution of genetic and environmental liability at two age points. At later age points, cases are more similar to controls compared to earlier age points. (B) Prevalent case association accuracy (purple), incident case prediction accuracy (red), and Incident case prediction under the EA model (grey) across different age quintiles of cases. Prediction accuracy is measured by observed-scale R^2 in 1:1 case-control matched samples, AUC, and liability scale R^2 (C) Incident case prediction accuracy of predictors with different liability-scale R^2.

818
819 **Figure 5: Age-dependent incident case prediction accuracy in 9 diseases.** (A) Cox log hazard
820 ratio of PRS on 9 diseases across 5 age quintiles. Each age bin has the same number of cases and
821 1:1 case-control ratio. Bars show standard error. (B) Age-dependent incident case prediction
822 compared to prevalent case association accuracy in 9 diseases. Numerical results are provided in
823 **Supplementary Table 13-14**.
824
825

Figure 6: Liability-threshold model and the EA model explain age-dependent PRS prediction accuracy. (A) 10-year change in QRS prediction R^2 under the liability-threshold model versus 10-year change in PRS prediction R^2 for 9 disease traits. (B) 10-year heritability change in estimated disease liability versus 10-year change in PRS prediction R^2 for corresponding disease traits. (C) 10-year change in QRS prediction R^2 under the liability-threshold+EA model versus 10-year change in PRS prediction R^2 for 9 disease traits. Diagonal line has slope equals to 1. Bars show the se and color shows the z-score of difference in X and Y values of each dot. τ is the proportion of observed decrease in PRS accuracy explained by each model (**Methods**). Numerical results are provided in **Supplementary Table 15-17**. We note that no estimates are significantly outside the plausible range and that allowing estimates outside of the plausible range is necessary to ensure unbiasedness of estimates.

Figure 7. Risk models with higher liability-scale R^2 are less attenuated when predicting late-onset diseases. (A) Age-dependent prediction accuracy of predictors averaged across 9 diseases. X-axis shows the per-10-year change of prediction R^2 computed in 1-1 case control matching groups. QRS: predicted liability using 36 quantitative traits. Top 3: linear predictors use the top three quantitative traits that have the highest correlation with the diseases. Single (Strong): using a single quantitative trait to predict incident diseases, averaged across the top three traits as in the "Top 3" group; Single (Weak): the average between 4th and 5th predictor of each disease. (B) Scatter plot comparing the liability-scale R^2 (without age stratification) with the change of R^2 w.r.t. age across predictor-disease pairs. Predictor-disease pairs are grouped into 10 deciles based on liability-scale R^2 for visualization. The red line shows a regression line with confidence interval. Numerical results are provided in **Supplementary Table 18-19**.

References:

1. Simino, J. *et al.* Gene-age interactions in blood pressure regulation: a large-scale investigation with the CHARGE, Global BPgen, and ICBP Consortia. *Am. J. Hum. Genet.* **95**, 24–38 (2014).

2. Robinson, M. R. *et al.* Genotype-covariate interaction effects and the heritability of adult body mass index. *Nat. Genet.* **49**, 1174–1181 (2017).

3. Winkler, T. W. *et al.* Genetic-by-age interaction analyses on complex traits in UK Biobank and their potential to identify effects on longitudinal trait change. *Genome Biol.* **25**, 300 (2024).

4. Miao, J. *et al.* PIGEON: a statistical framework for estimating gene-environment interaction for polygenic traits. *Nat. Hum. Behav.* 1–15 (2025).

5. Zhu, C. *et al.* Amplification is the primary mode of gene-by-sex interaction in complex human traits. *Cell Genomics* **3**, (2023).

6. Jiang, X., Holmes, C. & McVean, G. The impact of age on genetic risk for common diseases. *PLoS Genet.* **17**, e1009723 (2021).

7. Sakaue, S. *et al.* Trans-biobank analysis with 676,000 individuals elucidates the association of polygenic risk scores of complex traits with human lifespan. *Nat. Med.* **26**, 542–548 (2020).

8. Jukarainen, S. *et al.* Genetic risk factors have a substantial impact on healthy life years. *Nat. Med.* **28**, 1893–1901 (2022).

9. Dahl, A. *et al.* A Robust Method Uncovers Significant Context-Specific Heritability in Diverse Complex Traits. *Am. J. Hum. Genet.* **106**, 71–91 (2020).

10. Pazokitoroudi, A. *et al.* A scalable and robust variance components method reveals insights

into the architecture of gene-environment interactions underlying complex traits. *Am. J.*

Hum. Genet. **111**, 1462–1480 (2024).

11. Thompson, D. J. *et al.* A systematic evaluation of the performance and properties of the UK

Biobank Polygenic Risk Score (PRS) Release. *PLoS One* **19**, e0307270 (2024).

12. Argentieri, M. A. *et al.* Integrating the environmental and genetic architectures of aging and

mortality. *Nat. Med.* **31**, 1016–1025 (2025).

13. Durvasula, A. & Price, A. L. Distinct explanations underlie gene-environment interactions

in the UK Biobank. *Am. J. Hum. Genet.* **112**, 644–658 (2025).

14. Zaitlen, N. *et al.* Informed conditioning on clinical covariates increases power in case-

control association studies. *PLoS Genet.* **8**, e1003032 (2012).

15. Pedersen, E. M. *et al.* Accounting for age of onset and family history improves power in

genome-wide association studies. *Am. J. Hum. Genet.* **109**, 417–432 (2022).

16. Aschard, H., Zaitlen, N., Lindström, S. & Kraft, P. Variation in predictive ability of

common genetic variants by established strata: the example of breast cancer and age.

Epidemiology **26**, 51–58 (2015).

17. Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in

large cohorts. *Nat. Genet.* **47**, 284–290 (2015).

18. Weissbrod, O. *et al.* Leveraging fine-mapping and multipopulation training data to improve

cross-population polygenic risk scores. *Nat. Genet.* **54**, 450–458 (2022).

19. Fry, A. *et al.* Comparison of sociodemographic and health-related characteristics of UK

Biobank participants with those of the general population. *Am. J. Epidemiol.* **186**, 1026–

1034 (2017).

20.   Tibshirani, R. Regression shrinkage and selection via the lasso. *Journal of the royal*

statistical society series b-methodological **58**, 267–288 (1996).

21.   Udler, M. S. *et al.* Type 2 diabetes genetic loci informed by multi-trait associations point to

disease mechanisms and subtypes: A soft clustering analysis. *PLoS Med.* **15**, e1002654

(2018).

22.   Jiang, X. *et al.* Age-dependent topic modeling of comorbidities in UK Biobank identifies

disease subtypes with differential genetic risk. *Nat. Genet.* **55**, 1854–1865 (2023).

23.   Suzuki, K. *et al.* Genetic drivers of heterogeneity in type 2 diabetes pathophysiology.

Nature 1–11 (2024).

24.   Celentano, D. D., Szklo, M. & Farag, Y. *Gordis Epidemiology*. (Elsevier - Health Sciences

Division, Philadelphia, PA, 2024).

25.   Khera, A. V. *et al.* Genome-wide polygenic scores for common diseases identify individuals

with risk equivalent to monogenic mutations. *Nat. Genet.* **50**, 1219–1224 (2018).

26.   Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via

Bayesian regression and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).

27.   Privé, F., Arbel, J. & Vilhjálmsson, B. J. LDpred2: better, faster, stronger. *Bioinformatics*

36, 5424–5431 (2021).

28.   Zheng, Z. *et al.* Leveraging functional genomic annotations and genome coverage to

improve polygenic prediction of complex traits within and between ancestries. *Nat. Genet.*

56, 767–777 (2024).

29.   SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk

prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in

Europe. *Eur. Heart J.* **42**, 2439–2454 (2021).

30. Patel, A. P. *et al.* A multi-ancestry polygenic risk score improves risk prediction for

coronary artery disease. *Nat. Med.* **29**, 1793–1803 (2023).

31. Lee, S. H., Goddard, M. E., Wray, N. R. & Visscher, P. M. A better coefficient of

determination for genetic profile analysis. *Genet. Epidemiol.* **36**, 214–224 (2012).

32. Chatterjee, N., Shi, J. & García-Closas, M. Developing and evaluating polygenic risk

prediction models for stratified disease prevention. *Nat. Rev. Genet.* **17**, 392–406 (2016).

33. Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of

polygenic risk scores. *Nat. Rev. Genet.* **19**, 581–590 (2018).

34. Kullo, I. J. *et al.* Polygenic scores in biomedical research. *Nat. Rev. Genet.* **23**, 524–532

(2022).

35. Kullo, I. J. Promoting equity in polygenic risk assessment through global collaboration. *Nat.*

Genet. **56**, 1780–1787 (2024).

36. Genomic data in the All of Us Research Program. *Nature* 1–7 (2024).

37. Dempster, E. R. & Lerner, I. M. Heritability of threshold characters. *Genetics* **35**, 212–236

(1950).

38. Wray, N. R. & Goddard, M. E. Multi-locus models of genetic risk of disease. *Genome Med.*

2, 10 (2010).

39. Lee, S. H., Wray, N. R., Goddard, M. E. & Visscher, P. M. Estimating missing heritability

for disease from genome-wide association studies. *Am. J. Hum. Genet.* **88**, 294–305 (2011).

40. Witte, J. S., Visscher, P. M. & Wray, N. R. The contribution of genetic variants to disease

depends on the ruler. *Nat. Rev. Genet.* **15**, 765–776 (2014).

41.   Hujoel, M. L. A., Gazal, S., Loh, P.-R., Patterson, N. & Price, A. L. Liability threshold

944   modeling of case-control status and family history of disease increases association power.

945   *Nat. Genet.* **52**, 541–547 (2020).

946   42.   Hujoel, M. L. A., Loh, P.-R., Neale, B. M. & Price, A. L. Incorporating family history of

947   disease improves polygenic risk scores in diverse populations. *Cell Genom.* **2**, 100152

948   (2022).

949   43.   Pedersen, E. M. *et al.* ADuLT: An efficient and robust time-to-event GWAS. *Nat. Commun.*

950   **14**, 5553 (2023).

951   44.   Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow

952   Development and Initial Evaluation. *JMIR Med Inform* **7**, e14325 (2019).

953   45.   Kofink, D. *et al.* Statin Effects on Metabolic Profiles: Data From the PREVEND IT

954   (Prevention of Renal and Vascular End-stage Disease Intervention Trial). *Circ. Cardiovasc.*

955   *Genet.* **10**, (2017).

956   46.   Wu, J. *et al.* A summary of the effects of antihypertensive medications on measured blood

957   pressure. *Am. J. Hypertens.* **18**, 935–942 (2005).

958   47.   Esposito, K., Chiodini, P., Bellastella, G., Maiorino, M. I. & Giugliano, D. Proportion of

959   patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes:

960   systematic review of 218 randomized controlled trials with 78 945 patients. *Diabetes Obes.*

961   *Metab.* **14**, 228–233 (2012).

962   48.   Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from

963   polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).

964   49.   Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models

965   via coordinate descent. *J. Stat. Softw.* **33**, 1–22 (2010).

966   50. Tay, J. K., Narasimhan, B. & Hastie, T. Elastic net regularization paths for all generalized

967   linear models. *J. Stat. Softw.* **106**, 1–31 (2023).